Generic vs Brand Name Drugs
|
|
|
- Alexa Reed
- 2 years ago
- Views:
Transcription
1 Generic vs Brand Name Drugs
2 About Generic vs Brand Drugs Generic medicines are FDA approved replica of branded medicines Generic medicines show the same therapeutic effects as branded medicines Brand Name vs Generic Drugs has a huge difference in their market price Generics are produced when a brand patent is expired
3 Q1. What is a generic drug? Ans: A generic drug is the same replica of the branded medicine, which is actively composed of the same active ingredient as the brand name drug and provides the same therapeutic effect. Both the counterparts are the same in terms of dosing, safety, strength, quality, mechanism, dosage, etc.
4 Q2. Are generic drugs safe as brand-name drugs? Ans: Yes. Both versions are safe to use. Generic medicines are also approved by the FDA before reaching the market.
5 Q2. Are generic drugs safe as brand-name drugs? Ans: Yes. Both versions are safe to use. Generic medicines are also approved by the FDA before reaching the market.
6 Q3. Why are generic drugs cheaper? Ans: Generics are affordable as they do not have to replicate the original clinical trials for the effectiveness and safety of the drug, which lowers the cost of the drug.
7 Q4. Why do generic and brand-name drugs look different? Ans: In the United States, trademark laws do not permit generic medication to look same as brand versions. However, generic medications should contain the same active components. Colors, flavors, and certain other inactive ingredients are usually different.
8 Contact Us At: Website: Toll-Free:
9
Practical Strategies for Biotechnology and Medical Device Companies to Manage Intellectual Property Rights
Practical Strategies for Biotechnology and Medical Device Companies to Manage Intellectual Property Rights Matt Jonsen Dorsey & Whitney LLP Angie Morrison Dorsey & Whitney LLP Intellectual Property Patents
The MHRD Chair on IPR National Law School of India University
The MHRD Chair on IPR National Law School of India University Conference on America Invents Act 2011 9 th January 2012 Keynote Address: Naren Thappeta US Patent Attorney/India Patent Agent www.iphorizons.com
Developing Countries in the Globalization of Pharmaceutical Patenting
Developing Countries in the Globalization of Pharmaceutical Patenting Ken Shadlen Department of International Development London School of Economics and Political Science (LSE) Stanford University Library
ACCOUNTING TREATMENT OF INTELLECTUAL PROPERTY IN THE PHARMACEUTICAL INDUSTRY
Trakia Journal of Sciences, Vol. 9, No 4, pp 63-68, 2011 Copyright 2011 Trakia University Available online at: http://www.uni-sz.bg ISSN 1313-7069 (print) ISSN 1313-3551 (online) Original Contribution
Intellectual Property
Intellectual Property Johnson & Johnson believes that the protection of intellectual property (IP) is essential to rewarding innovation and promoting medical advances. We are committed: to raising awareness
eskbook Emerging Life Sciences Companies second edition Chapter 8 Checklist for Planning and Conducting an Effective FTO Search
eskbook Emerging Life Sciences Companies second edition Chapter 8 Checklist for Planning and Conducting an Effective FTO Search Chapter 8 CHECKLIST FOR PLANNING AND CONDUCTING AN EFFECTIVE FTO SEARCH The
TRIPS and Access to Medicines. WR Briefing
TRIPS and Access to Medicines WR Briefing Outline What is TRIPS How does it affect access to medicines What are the TRIPS flexibilities? What are extra-trips provisions? How do the extra-trips provisions
Local Production of Pharmaceuticals and Related Technology Transfer UNCTAD/CD-TFT 1. Background
Local Production of Pharmaceuticals and Related Technology Transfer Dr. Padmashree Gehl Sampath Division for Technology and Logistics UNCTAD UNCTAD/CD-TFT 1 1 Background Case studies part of the EU funded
ROLE OF INTELLECTUAL PROPERTY RIGHTS IN DEVELOPING COUNTRIES -ASHWINI SANDU.
ROLE OF INTELLECTUAL PROPERTY RIGHTS IN DEVELOPING COUNTRIES -ASHWINI SANDU. Can you guess? How does one protect their brand? Most brands are distinct and being distinctive is the way potential users
Enforcement Regulations of the Pharmaceutical Affairs Law
Enforcement Regulations of the Pharmaceutical Affairs Law The Enforcement Regulations of the Pharmaceutical Affairs Law ( PAL ) shall be amended, in part, as follows: Article 24 (Product approval application
Access to Technology in the Post-2015 Development Agenda. Alessandra Casazza Policy Advisor UNDP Asia-Pacific Regional Center
Access to Technology in the Post-2015 Development Agenda Alessandra Casazza Policy Advisor UNDP Asia-Pacific Regional Center TECHNOLOGY IS ESSENTIAL FOR ACHIEVING SUSTAINABLE DEVELOPMENT MDG 8 ICT & Access
EU GMP Evolution or Revolution Scope and drivers for EU GMP changes. August Gordon Farquharson
EU GMP Evolution or Revolution Scope and drivers for EU GMP changes August 2015 Gordon Farquharson EU & PIC/S Harmonisation at IWG level now Slide 2 PharmOut 2015 EU & PIC/S Harmonisation (1) What does
The Face of the Patent is not the Whole Story : Determining Effective Patent Life in the US. Anne Marie Clark, Ph.D. and Heidi Berven,, Ph.D., J.D.
The Face of the Patent is not the Whole Story : Determining Effective Patent Life in the US Anne Marie Clark, Ph.D. and Heidi Berven,, Ph.D., J.D. Interface Between Patent Term and Regulatory Exclusivity
Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum
Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum List of recommendations: Recommendation 1: That the government creates a Life Sciences
US-ANDEAN FREE TRADE AGREEMENT IMPACT ON ACCESS TO MEDICINES AND HEALTH IN COLOMBIA
US-ANDEAN FREE TRADE AGREEMENT IMPACT ON ACCESS TO MEDICINES AND HEALTH IN COLOMBIA Germán Holguín General Director, Health Mission Foundation Bogotá, Colombia, November, 2005 ACCESS TO THE MEDICINES:
The ability to capture health information
TRENDING 2017 Smart Technology Published in November/December 2016 Copyright 2016 by PharmaLinx LLC Trending 2017: Smart Technology From electronic biomedical implants that dissolve within the body to
Breakfast briefing: Ross DeVol Chief Research Officer Milken Institute September 22, 2011 The Phoenix Park Hotel Washington, DC
Breakfast briefing: Ross DeVol Chief Research Officer Milken Institute September 22, 2011 The Phoenix Park Hotel Washington, DC Study overview Part 1: The Global Biomedical Industry: Understanding the
Study overview. The Global Biomedical Industry: Preserving U.S. Leadership
Presentation for: Voluntary Health Leadership Conference February 9, 2012 Rancho Bernardo Inn San Diego, CA Ross DeVol Chief Research Officer Milken Institute Study overview Part 1: Understanding the Factors
Office of Pharmaceutical Quality Key Quality Initiatives
Office of Pharmaceutical Quality Key Quality Initiatives Ashley B. Boam, MSBE Director Office of Policy for Pharmaceutical Quality Office of Pharmaceutical Quality Center for Drug Evaluation and Research
PATENT PROTECTION FOR PHARMACEUTICAL PRODUCTS IN CANADA CHRONOLOGY OF SIGNIFICANT EVENTS
PRB 99-46E PATENT PROTECTION FOR PHARMACEUTICAL PRODUCTS IN CANADA CHRONOLOGY OF SIGNIFICANT EVENTS Margaret Smith Law and Government Division 30 March 2000 Revised 31 May 2000 PARLIAMENTARY RESEARCH BRANCH
China: Managing the IP Lifecycle 2018/2019
China: Managing the IP Lifecycle 2018/2019 Patenting strategies for R&D companies Vivien Chan & Co Anna Mae Koo and Flora Ho Patenting strategies for R&D companies By Anna Mae Koo and Flora Ho, Vivien
Debra Young, PHR Executive Vice President DHR International, Inc.
Debra Young, PHR Executive Vice President DHR International, Inc. Debra s Background DU graduate with BM and MA degrees PHR Certified Human Resources Management Certification, Villanova University Paralegal
Scripps Florida. Accelerating Discoveries, Saving Lives. Presentation to the Urban Land Institute November 4, 2011
Scripps Florida Accelerating Discoveries, Saving Lives Presentation to the Urban Land Institute November 4, 2011 Alex Bruner Associate Vice President, Philanthropy 1921- Founding of the Scripps Metabolic
EVERGREENING OF PATENT
Bharati Law Review, Oct. Dec., 2014 101 EVERGREENING OF PATENT Dr. Vijay Oak Introduction Patent is a monopoly right given for a limited period to an inventor who has made a new, useful and non-obvious
Health Technology Assessment of Medical Devices in Low and Middle Income countries: challenges and opportunities
Health Technology Assessment of Medical Devices in Low and Middle Income countries: challenges and opportunities Aleksandra Torbica, Carlo Federici, Rosanna Tarricone Centre for Research on Health and
Implantable Drug Delivery Devices Market - Global Industry Analysis, Size, Share, Trends And Forecast,
Transparency Market Research Implantable Drug Delivery Devices Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 2018 Buy Now Request Sample Published Date: Mar 2013 Single User
ASSOCIATION INTERNATIONALE DE LA MUTUALITE. Pharmaceutical Sector Inquiry Preliminary Report 28 November AIM Response 2 February 2009
AIM ASSOCIATION INTERNATIONALE DE LA MUTUALITE Pharmaceutical Sector Inquiry Preliminary Report 28 November 2008 AIM Response 2 February 2009 AIM would like to thank DG Competition for having taken the
ISPFILMQATM STATE-OF-THE-ART RADIOTHERAPY VERIFICATION SOFTWARE. Supports all major radiotherapy technologies! FilmQA TM
FILMQA STATE-OF-THE-ART RADIOTHERAPY VERIFICATION SOFTWARE Supports all major radiotherapy technologies! FilmQA is optimized for use with Gafchromic film products, including EBT2 and RTQA2. FILMQA helps
Study of Comparative Advantages of Chinese and Indian Pharmaceutical Industries under Globalization
MANAGEMENT SCIENCE AND ENGINEERING Vol. 4, No. 4, 2010, pp. 82-86 www.cscanada.org ISSN 1913-0341 [Print] ISSN 1913-035X [Online] www.cscanada.net Study of Comparative Advantages of Chinese and Indian
Where do patent measures fall short in the life sciences? Bhaven N. Sampat Columbia University and NBER July 28, 2017
Where do patent measures fall short in the life sciences? Bhaven N. Sampat Columbia University and NBER July 28, 2017 There are well-known problems with patent statistics In most sectors patents not as
Managing Intellectual Property Assets: The NIH OTT Perspective
2009/SOM1/IPEG/SEM/003 Session: 2 Managing Intellectual Property Assets: The NIH OTT Perspective Submitted by: United States From Mind to Market: The Highs and Lows of Technology Transfer Singapore 23-24
E5 Implementation Working Group Questions & Answers (R1) Current version dated June 2, 2006
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE E5 Implementation Working Group & (R1) Current version dated June 2, 2006 ICH Secretariat,
Intellectual Property Policy. DNDi POLICIES
Intellectual Property Policy DNDi POLICIES DNDi hereby adopts the following intellectual property (IP) policy: I. Preamble The mission of DNDi is to develop safe, effective and affordable new treatments
Your Content Your Way
MY VIEW Your Content Your Way My View allows you to view only the topics you want to follow. Choose from a list of available topics, which are individualized for each publications, and design your own
Tapan Ray Director General Organisation of Pharmaceutical Producers of India ALCAN PACKAGING UNIVERSITY OCT 8, LONAVALA
COMBATING COUNTERFEIT DRUGS WITH PACKAGING TECHNOLOGY Tapan Ray Director General Organisation of Pharmaceutical Producers of India ALCAN PACKAGING UNIVERSITY OCT 8, 2009 -LONAVALA Content Counterfeit Medicines:
Access to current products and innovation for the future- Some community Thoughts. Kenly Sikwese Geneva 1 November 2011
Access to current products and innovation for the future- Some community Thoughts Kenly Sikwese Geneva 1 November 2011 Financing the response Current ART successes have been predicated on sustained new
TRIPs & PATENTS. In 1899, Mr. Charles H. Duell, Director of US Patent office said Everything that can be invented, has (already) been invented.
TRIPs & PATENTS Dr.Gopakumar G. Nair In 1899, Mr. Charles H. Duell, Director of US Patent office said Everything that can be invented, has (already) been invented. The events thereafter proved that inventions
Implementation of Systems Medicine across Europe
THE CASyM ROADMAP Implementation of Systems Medicine across Europe A short roadmap guide 0 The road toward Systems Medicine A new paradigm for medical research and practice There has been a data generation
Chapter 15: Access to essential medicines, TRIPS and the patent system
Chapter 15: Access to essential medicines, TRIPS and the patent system SUMMARY POINTS All countries should develop a national medicines policy that includes a national list of essential medicines that
Quality assurance in the supply chain for pharmaceuticals from the WHO perspective
1 Quality assurance in the supply chain for pharmaceuticals from the WHO perspective Dr Sabine Kopp Quality Assurance and Safety: Medicines Medicines Policy and Standards World Health Organization Presentation
Regional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities
REPUBLIC OF SOUTH AFRICA Regional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities Topic 7: Flexibilities Related to the Definition of Patentable
TION INDIA THE RIGHT CHOICE FOR THE PHARMACEUTICAL INDUSTRY
Delhi Business Review X Vol. 7, No. 1 (January - June 2006) DESTINATIO TION INDIA THE RIGHT CHOICE FOR THE PHARMACEUTICAL INDUSTRY Alka Chadha* I NTRODUCTION THE drugs and pharmaceutical industry has an
A Brief Introduction to the Regulatory Environment of Medical Device Supervision. CFDA Department of Legal Affairs Liu Pei
A Brief Introduction to the Regulatory Environment of Medical Device Supervision CFDA Department of Legal Affairs Liu Pei Development Trend of Medical Device Industry Development Opportunities of Medical
Dr. Reddy s Laboratories PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM
Dr. Reddy s Laboratories PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2018-2020 Since 1984, Dr. Reddy s has succeeded in its purpose of providing affordable and innovative medicines for healthier lives.
Draft global strategy on public health, innovation and intellectual property
IGWG: Outcome document at 14.00 hours, Saturday 3 May 2008 Draft global strategy on public health, innovation and intellectual property The context 1. In resolution WHA59.24 the Health Assembly recognized
8/2/2017. Radiologist Responsibilities. Radiologist Responsibilities. Medical Physicist Mammography Equipment Evaluation and Annual Survey
Implementation of the 2016 ACR Digital Mammography QC Manual Medical Physicist Mammography Equipment Evaluation and Annual Survey Eric A Berns, PhD, FACR Radiologist Responsibilities Radiologist Responsibilities
APIs global business developments
APIs global business developments Dr Gian Mario Baccalini EFCG Board Member, Chairman of EFCG Pharma Business Committee President & CEO, Euticals S.p.A., Italy EFCG Press Conference, 13th October 2015,
The Importance of Taking Your Pills on Schedule
The Importance of Taking Your Pills on Schedule CANCERCARE CONNECT BOOKLET SERIES WWW.CANCERCARE.ORG The Importance of Taking Your Pills on Schedule The CancerCare Connect Booklet Series offers up-to-date,
Towards malaria elimination: ADB-supported work at Myanmar FDA
Towards malaria elimination: ADB-supported work at Myanmar FDA Valerio Reggi 25 January 2018 Disclaimer: The views expressed in this paper/presentation are the views of the author and do not necessarily
UNITAID The HIV/AIDS Medicines Patent Pool Initiative Overview
UNITAID The HIV/AIDS Medicines Patent Pool Initiative Overview December 2009 UNITAID Mission UNITAID's Mission Scale up access to treatment for HIV/AIDS, malaria and TB Leverage price reductions of quality
Death from the Public Domain?
Boston University School of Law Scholarly Commons at Boston University School of Law Faculty Scholarship 2009 Death from the Public Domain? Kevin Outterson Boston Univeristy School of Law Follow this and
FOREST LABORATORIES, INC. AND DAIICHI SANKYO, INC. ANNOUNCE THE TERMINATION OF THE AZOR CO-PROMOTION AGREEMENT
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
FP187: DMF in Multiple Sclerosis
FP187: DMF in Multiple Sclerosis Jefferies Healthcare Conference June 3, 2015 Forward-Looking Statements This presentation contains forward-looking statements about Forward Pharma A/S based on management
Pharma Session 4: Digital health your health on (the) line
Pharma Session 4: Digital health your health on (the) line Monday, October 16 2017 16:00-17:30 www.aippi.orgg Niklas Mattsson, Awapatent (moderator) Leonore Ryan, formerly of CSIRO and Cardihab Jonathan
Observations from Pharma
Observations from Pharma Indian Patent Enforcement in the Chemical Arts Gurmeet Kaur Sidhu, Senior Patent Litigation Counsel London, 26/9/11 a Novartis company The Indian Pharmaceutical sector: Overview
Management to Host Conference Call at 8:30 a.m. ET today
Aclaris Therapeutics Reports Second Quarter 2016 Financial Results August 11, 2016 7:01 AM ET Management to Host Conference Call at 8:30 a.m. ET today MALVERN, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:ACRS),
Progressive Licensing and the Modernization of the Canadian Regulatory Framework
Progressive Licensing and the Modernization of the Canadian Regulatory Framework Workshop on Implementation of ICH Quality Guidelines Beijing, China 3-5 December, 2008 Mike Ward Health Canada 1 DISCLAIMER
PROPOSAL TEMPLATE. Patent Duration and Collusive Behaviour to Postpone R&D for Innovative Treatments
PROPOSAL TEMPLATE Proposal Name: Patent Duration and Collusive Behaviour to Postpone R&D for Innovative Treatments Submitted by: Pr. Patrick Leoni - Euromed Management (France) E-mail: patrick.leoni@euromed-management.com
The Shape of Things to Come Strategies for Success in the Age of 3D Printing. Husch Blackwell LLP
The Shape of Things to Come Strategies for Success in the Age of 3D Printing Husch Blackwell LLP What is 3D Printing and How Does it Work? State of 3D Printing As of 2014: 80,000 industrial printers worldwide
Lundbeck s view on the EU IP systems
Lundbeck s view on the EU IP systems Forårsmøde IPR in the EU May 26 2011 H. Lundbeck A/S 1 Agenda The Innovative Pharmaceutical Industry and why IP is so important for Lundbeck Lundbeck s wish list for
EMA experience with the review of digital technology proposals in medicine development programmes
EMA experience with the review of digital technology proposals in medicine development programmes 3rd Industry Stakeholder Platform on R&D support, 18 May 2018 Francesca Cerreta, Scientific Advice An agency
CEOCFO Magazine. Pat Patterson, CPT President and Founder. Agilis Consulting Group, LLC
CEOCFO Magazine ceocfointerviews.com All rights reserved! Issue: July 10, 2017 Human Factors Firm helping Medical Device and Pharmaceutical Companies Ensure Usability, Safety, Instructions and Training
Mass Variation Tests for Coating Tablets and Hard Capsules: Rational Application of Mass Variation Tests
1176 Chem. Pharm. Bull. 50(9) 1176 1180 (00) Vol. 50, No. 9 Mass Variation Tests for Coating Tablets and Hard Capsules: Rational Application of Mass Variation Tests Noriko KATORI,* Nobuo AOYAGI, and Shigeo
Discovery: From Concept to the Patient - The Business of Medical Discovery. Todd Sherer, Ph.D.
Discovery: From Concept to the Patient - The Business of Medical Discovery Todd Sherer, Ph.D. Associate Vice President for Research and Director of OTT President Elect, Association of University Technology
The Transition to Model-Based Drug Development. Phase 1: Formalizing the Pharmacometric Process
1780 Wehrle Drive Suite 110 Buffalo, New York 14221 716.633.3463 cognigencorp.com The Transition to Model-Based Drug Development Phase 1: Formalizing the Pharmacometric Process By Thaddeus H. Grasela,
INVESTOR PRESENTATION!
INVESTOR PRESENTATION ENHANCING HEALTH THROUGH CANNABIS SCIENCE WWW.EMERALDHEALTH.CA TSX.V:EMH TSX.V:EMH Disclaimer THE STATEMENTS MADE IN THIS PRESENTATION MAY INCLUDE FORWARD-LOOKING STATEMENTS REGARDING
IN THE MATTER OF THE COMPETITION ACT, R.S.C. 1985, c. C-34, as am.
IN THE MATTER OF THE COMPETITION ACT, R.S.C. 1985, c. C-34, as am. AND IN THE MATTER OF A COMPLAINT CONCERNING ANTI-COMPETITIVE PRACTICES IN THE PHARMACEUTICAL INDUSTRY STATUTORY DECLARATION I, James Clancy,
Descriptions of Workshops and Pharma Workshops for Helsinki 2013
Descriptions of Workshops and Pharma Workshops for Helsinki 2013 1) IP licensing and insolvency The insolvency of technological giants such as Qimonda, BenQ or Kodak sends massive shockwaves into the world
Research Brief. Clinicians and life sciences companies working together: What types of relationships do clinicians find most appealing?
Research Brief Clinicians and life sciences companies working together: What types of relationships do Truven Health Analytics was acquired by IBM in 2016 to help form a new business, Watson Health. Watson
How machines learn in healthcare
ADVANCES IN DATA SCIENCE How machines learn in healthcare Machine learning is transforming every facet of healthcare, as computer systems are being taught how to use Big Data to derive insights and support
Considerations in Conforming Data from Multiple Implantable Medical Devices to CDISC Standards Using SAS Julia Yang, Medtronic plc.
Considerations in Conforming Data from Multiple Implantable Medical Devices to CDISC Standards Using SAS Julia Yang, Medtronic plc. Mounds View, MN ABSTRACT Both pharmaceutical and medical device trial
INTEGRATING INNOVATION AND CREATIVITY INTO NATIONAL POLICIES AND STRATEGIES OGADA T.
INTEGRATING INNOVATION AND CREATIVITY INTO NATIONAL POLICIES AND STRATEGIES OGADA T. High-Level Meeting for Members of Parliament of ARIPO Member States : Strategic Use of IP System for Economic, Cultural
Collaborating with the Office of Technology Transfer
Collaborating with the Office of Technology Transfer Todd Sherer, Ph.D. Associate Vice President for Research and Executive Director Office of Technology Transfer Emory Owns Our IP As a condition of employment,
ICH Q7 - API. Presented by Ashley Isbel 4 July, 2016
ICH Q7 - API Presented by Ashley Isbel 4 July, 2016 ICH Q7 ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (November 2000) Adopted or referenced by: PIC/S in 2007 - Guide
Enabling Technologies Energy Environmental Homeland Security Industrial Processes Information Technology
EDISON PATENT AWARD 2014 SUBMISSION GUIDELINES Established 52 years ago, the Research & Development Council of New Jersey has sustained its core mission of advancing research and development in New Jersey
Purpose of the summary
Summary of Expertise, Experience, and Affiliations and Interests Scientific Advisory Committee on Sciences and Clinical Pharmacology (SAC-PSCP) Purpose of the summary The following table summarizes the
Research and Development Spending
Patented Medicine Prices Review Board Le Conseil d examen du prix des médicaments brevetés PMPRB Study Series S-217 December 22 A Comparison of Pharmaceutical Research and Development Spending in Canada
peace of mind For from development to commercial supply
For peace of mind from development to commercial supply aesica-pharma.com weshouldtalk@aesica-pharma.com @aesica CorporateBroEng_v2 0814 @ Aesica 2014 Your full service CDMO Our vision: To be the number
Human Factors Studies
Human Factors Studies Generic Combination Products Moderator: David M. Fox, Partner Hogan Lovells, US LLP Panelist: Kirsten H. Paulson, Sr. Director Pfizer Inc. Global CMC-Medical Devices Panelist: Dick
Form FI. Management s Discussion and Analysis of Results of Operations and Financial condition for the six months ended April 30, 2007.
Form 51-102FI SERNOVA CORP. Management s Discussion and Analysis of Results of Operations and Financial condition for the six months ended April 30, 2007. The following discussion and analysis should be
The FDA: Merging Innovation and Opportunity to Impact Public Health
The FDA: Merging Innovation and Opportunity to Impact Public Health Jonathan Sackner-Bernstein, MD, FACC Associate Center Director, Post Market Operations Center for Devices and Radiologic Health U.S.
THE IMPACT OF FOREIGN PHARMACEUTICAL PATENTS ON INNOVATION IN CHILE
THE IMPACT OF FOREIGN PHARMACEUTICAL PATENTS ON INNOVATION IN CHILE Maria Jose Abud Sittler (INAPI, Chile) Bronwyn Hall (UC Berkeley) Christian Helmers (Universidad Carlos III Madrid IPSDM Tokyo, 18 November
Decision regarding PHARMAC s Implementation of Trans-Pacific Partnership (TPP) provisions and other Amendments to Application Processes
8 December 2016 Decision regarding PHARMAC s Implementation of Trans-Pacific Partnership (TPP) provisions and other Amendments to Application Processes PHARMAC is pleased to announce that changes will
ARE PATENTS REALLY LIMITED TO 20 YEARS? A CLOSER LOOK AT PHARMACEUTICALS. Melody Wirz. I. Introduction
Abstract Melody Wirz is a third year law student at The University of Oklahoma College of Law. She is a registered patent agent and has received a B.S. from Oklahoma State University as well as an M.B.A.
Regional Seminar on the Effective Implementation and Use of Several Patent-Related Flexibilities
DEPARTMENT OF INTELLECTUAL PROPERTY MINISTRY OF COMMERCE Regional Seminar on the Effective Implementation and Use of Several Patent-Related Flexibilities Topic 12: Which are Valid Grounds for a Compulsory
Regulation on medicinal products for paediatric use
Regulation on medicinal products for paediatric use ANWALTSKANZLEI STRÄTER Burkhard Sträter Kronprinzenstraße 20 53173 Bonn Tel.:++49-228 228-93454 93454-0 Fax.:++49-228 228-93454 93454-54 Mail@kanzleistraeter
SCIENTIFIC INTEGRITY
AFFORDABLE, WORLD-CLASS QUALITY PRODUCTS GROUNDED IN SCIENTIFIC INTEGRITY Our goal is to grow a global presence in prescription brands, generics, over the counter (OTC), and private label products through
How Paediatric Research Networks can help drug development
How Paediatric Research Networks can help drug development Mark Turner An agency of the European Union Why networks? Significant increase in trials and participants Delays are now significant Networks
Counterfeit Medicines Toolkit 4. Information about the International Medical Products Anti-Counterfeiting Taskforce (IMPACT)
Counterfeit Medicines Toolkit 4. Information about the International Medical Products Anti-Counterfeiting Taskforce (IMPACT) 1 International Collaboration: A Request of Medicine Regulatory Authorities
WANT TO PARTICIPATE IN RESEARCH? THERE S AN APP FOR THAT!
WANT TO PARTICIPATE IN RESEARCH? THERE S AN APP FOR THAT! SECURITY AND PRIVACY ISSUES WITH THE INCREASED USE OF CONNECTED DEVICES, APPS, AND SOCIAL MEDIA IN RESEARCH. PRESENTED BY: DAVID MATA, SENIOR ASSOCIATE,
Translational scientist competency profile
C-COMEND Competency profile for Translational Scientists C-COMEND is a two-year European training project supported by the Erasmus plus programme, which started on November 1st 2015. The overall objective
Cross-Border R&D in China Understanding the Regulatory Challenges
1 2 Cross-Border R&D in China Understanding the Regulatory Challenges 1 Panelists Moderator: Paul A. Stewart, Silicon Valley Office Managing Partner, Foley & Lardner LLP Speakers: David Rosen, Partner,
Design and Technology
2017 HIGHER SCHOOL CERTIFICATE EXAMINATION Design and Technology General Instructions Reading time 5 minutes Working time 1 1 2 hours Write using black pen Write your Centre Number and Student Number at
Leader in Pharmaceutical Films
TSX-V: IGX OTCQX: IGXT Leader in Pharmaceutical Films Your Specialist in Contract Development & Manufacturing WE MAKE APPROVED DRUGS BETTER Our Mission We make approved drugs better, with next generation
Technology UC San Diego
Technology Transfer @ UC San Diego David Gibbons, PE, MBA Assistant Director, Physical Sciences October 10, 2013 Technology Transfer Office TTO Goals the Mission Facilitate the transfer of useful technologies
What Makes International Research Ethical (Or Unethical)? Eric M. Meslin, Ph.D Indiana University Center for Bioethics
What Makes International Research Ethical (Or Unethical)? Eric M. Meslin, Ph.D Indiana University Center for Bioethics Why Should We Care? Volume of health research is increasing more researchers, more
Authors Heidi Gautschi Alexandre Raynaud Damien Vossion Michael Wade. Digital Patient Engagement. Insights for the Pharmaceutical Industry
Authors Heidi Gautschi Alexandre Raynaud Damien Vossion Michael Wade Digital Patient Engagement Insights for the Pharmaceutical Industry March 2018 2 DIGITAL PATIENT ENGAGEMENT: INSIGHTS FOR THE PHARMACEUTICAL
Innovation and the Changing Practice of Medicine
Innovation and the Changing Practice of Medicine Japan Medical Innovation Symposium David Epstein, Division Head Novartis Pharmaceuticals Tokyo, August 18, 2015 Agenda The Case for Innovation How Novartis
Practical Strategies for Managing Patent Rights for Biotechnology and Medical Device Companies
Practical Strategies for Managing Patent Rights for Biotechnology and Medical Device Companies Timothy A. Worrall, Ph.D. Partner Dorsey & Whitney LLP Brad J. Hattenbach Of Counsel Dorsey & Whitney LLP
W5 Application of Gamification in Healthcare and Outcomes measurement : Improving treatment compliance and research engagement
W5 Application of Gamification in Healthcare and Outcomes measurement : Improving treatment compliance and research engagement MICHAEL ACQUADRO, JOHN HARRISON, JURRIAAN VAN RIJSWIJK Discussion leaders